RESUMO
In 17 patients (14 men and 3 women aged 69 +/- 10 years), a transvenous pacemaker was implanted before (8 patients), following (7 patients), or simultaneously (2 patients) with the insertion of a transvenous defibrillator. Indications included malignant ventricular arrhythmias and symptomatic bradycardia in all patients. All patients had structural heart disease. All pacemakers were non-programmable bipolar, either single chamber (n = 7) or dual chamber (n = 10). Eleven pacemakers were rate responsive. The Transvene system was implanted in 7 patients (Pacer-Cardioverter-Defibrillator in 6 patients and the Cadence defibrillator in 1). The Endotak lead system was implanted in 10 patients (Ventak in 7 patients and the Cadence in 3). The mean defibrillation threshold was 16 +/- 5 J. Repositioning of the pacemaker leads eliminated undersensing of ventricular fibrillation by the defibrillator, which occurred during asynchronous pacing in 2 patients. During a mean follow-up of 11 +/- 6 months, 2 patients died because of pump failure and 7 patients received defibrillator therapy for ventricular arrhythmias. No significant complications were noted. Successful concomitant implantation of transvenous pacemakers and defibrillators was thus accomplished in 17 patients, which suggests that insertion of a second transvenous device can be safely accomplished.
Assuntos
Arritmias Cardíacas/terapia , Desfibriladores Implantáveis , Marca-Passo Artificial , Adulto , Idoso , Idoso de 80 Anos ou mais , Desenho de Equipamento , Estudos de Viabilidade , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
Because postdefibrillation bradycardia or asystole is of clinical concern in patients with implanted automatic cardioverter defibrillators, we analyzed the cardiac rhythm after 157 intraoperative defibrillations in 50 patients undergoing implantation of the device. Factors that could influence the heart rhythm immediately after defibrillation were also analyzed. The postdefibrillation heart rate and the duration of postdefibrillation asystole did not correlate with age, conduction abnormalities, type or duration of arrhythmia before defibrillation, delivered energy, lead system, or left ventricular ejection fraction, but they did correlate with the resting preoperative heart rate and the concomitant performance of coronary artery bypass surgery at the time of defibrillator implantation. Temporary pacing (for prolonged asystole) was required in only two patients, both of whom had also undergone bypass surgery. Fourteen patients being treated with amiodarone had slower resting and postdefibrillation heart rates, but the mean duration of posdefibrillation asystole was similar to that seen in patients not receiving any antiarrhythmic medication. On follow-up, 25 monitored and 178 unmonitored automatic defibrillator discharges occurred in 24 patients, without evidence of symptomatic postdefibrillation bradyarrhythmias. Thus significant postdefibrillation bradyarrhythmias were uncommon, but when such a propensity existed it could not be predicted reliably on clinical grounds alone.